Prévalence de la sclérose en plaques en France en 2012 et mortalité associée en 2013 à partir des données du Sniiram-PMSI, Rev DÉpidémiologie Santé Publique. 1 mars, vol.63, pp.17-25, 2015. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996. ,
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-73, 2018. ,
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis, Mult Scler Houndmills Basingstoke Engl. sept, vol.18, issue.9, pp.1290-1296, 2012. ,
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsingremitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial, Lancet Neurol. juin, vol.8, issue.6, pp.519-548, 2009. ,
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.416-442, 2010. ,
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617750
Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, vol.365, issue.14, pp.1293-303, 2011. ,
Simvastatin as add-on therapy to interferon ?-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial, Lancet Neurol. août, vol.10, issue.8, pp.691-701, 2011. ,
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, doubleblind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013. ,
Statistical methods for the analysis of relapse data in MS clinical trials, J Neurol Sci, vol.15, issue.1-2, pp.206-217, 2009. ,
Surdispersion et modèle binomial négatif généralisé, Rev Stat Appliquée, vol.50, issue.3, pp.73-86, 2002. ,
Sample size calculation for comparing two negative binomial rates, Stat Med. 10 févr, vol.33, issue.3, pp.376-87, 2014. ,
Promoting public access to clinical trial protocols: challenges and recommendations, Trials, vol.17, 2018. ,
Statistical methods for the analysis of relapse data in MS clinical trials, J Neurol Sci, vol.15, issue.1-2, pp.206-217, 2009. ,
Sample size calculation for comparing two negative binomial rates, Stat Med. 10 févr, vol.33, issue.3, pp.376-87, 2014. ,
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017. ,
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013. ,
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol. mars, vol.13, issue.3, pp.247-56, 2014. ,
Placebocontrolled trial of oral laquinimod for multiple sclerosis, N Engl J Med. 15 mars, vol.366, issue.11, pp.1000-1009, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00826733
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.373, issue.15, pp.1418-1446, 2015. ,
Randomized study combining interferon and glatiramer acetate in multiple sclerosis, Ann Neurol. mars, vol.73, issue.3, pp.327-367, 2013. ,
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.416-442, 2010. ,
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617750
Phase III dose-comparison study of glatiramer acetate for multiple sclerosis, Ann Neurol. janv, vol.69, issue.1, pp.75-82, 2011. ,
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis, Ann Neurol. juin, vol.73, issue.6, pp.705-718, 2013. ,
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial, Lancet Neurol. juin, vol.8, issue.6, pp.519-548, 2009. ,
Simvastatin as add-on therapy to interferon ?-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial, Lancet Neurol. août, vol.10, issue.8, pp.691-701, 2011. ,
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol. juin, vol.13, issue.6, pp.545-56, 2014. ,
Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, Lancet Neurol. juill, vol.13, issue.7, pp.657-65, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01097451
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial, Lancet Neurol. janv, vol.15, issue.1, pp.35-46, 2016. ,
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. août, vol.15, issue.8, pp.965-76, 2009. ,
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617764
Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, vol.365, issue.14, pp.1293-303, 2011. ,
Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, N Engl J Med, vol.367, issue.12, pp.1087-97, 2012. ,
Assessing changes in relapse rates in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. déc, vol.16, issue.12, pp.1414-1435, 2010. ,
Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression, Mult Scler Houndmills Basingstoke Engl. oct, vol.19, issue.12, pp.1580-1586, 2013. ,
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis, Mult Scler Houndmills Basingstoke Engl. sept, vol.18, issue.9, pp.1290-1296, 2012. ,
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network metaanalysis. Cochrane Database Syst Rev, p.11381, 2015. ,
Planning a future randomized clinical trial based on a network of relevant past trials, Trials. 11 juill, vol.19, issue.1, p.365, 2018. ,
GetReal Workpackage 1. The inclusion of real world evidence in clinical development planning, Trials. 29 août, vol.19, issue.1, p.468, 2018. ,
Statistical review: frequently given comments, Ann Rheum Dis. févr, vol.74, issue.2, pp.323-328, 2015. ,
Time to first relapse as an endpoint in multiple sclerosis clinical trials, Mult Scler Houndmills Basingstoke Engl. avr, vol.19, issue.4, pp.466-74, 2013. ,
Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials, Methods Inf Med, vol.49, issue.6, pp.618-642, 2010. ,
Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis, Pharm Stat, vol.18, issue.3, pp.351-65, 2019. ,
Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials, J Neurol Sci. 1 févr, vol.163, issue.1, pp.74-80, 1999. ,